Hypersensitivity - Antibody Mediated Types II and III

Type II and Type III Hypersensitivity Reactions Introduction Type II and Type III hypersensitivity reactions both involve antibodies, but they work through fundamentally different mechanisms. Type II hypersensitivity occurs when antibodies directly bind to antigens on cell surfaces or tissue components, causing damage through complement activation or antibody-dependent cellular toxicity. Type III hypersensitivity involves circulating immune complexes—collections of antigens and antibodies floating in the bloodstream—that deposit in tissues and cause damage indirectly through complement activation and inflammation. This distinction is crucial because it determines how diseases manifest and how they're diagnosed and treated. Type II Cytotoxic Antibody-Mediated Hypersensitivity How Type II Hypersensitivity Works In Type II hypersensitivity, antibodies recognize and bind to antigens that are fixed in place—either on cell surfaces, tissue membranes, or basement membranes. Once bound, these antibodies trigger destruction of the target cells or tissues through two main pathways: complement activation or antibody-dependent cellular cytotoxicity (ADCC). An important distinction to understand: antibodies in Type II reactions can behave in opposite ways depending on the disease. Antibodies as agonists (stimulators): In some diseases, antibodies actually stimulate cellular receptors instead of just blocking them. The classic example is Graves' disease (autoimmune hyperthyroidism), where antibodies bind to and activate the thyroid-stimulating hormone (TSH) receptor on thyroid cells, causing excessive thyroid hormone production. Antibodies as antagonists (blockers): In other diseases, antibodies block normal receptor function. Myasthenia gravis is the textbook example: antibodies bind to acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and blocking nerve-muscle communication. Diagnosis of Type II Hypersensitivity The Coombs tests are the gold-standard diagnostic tools for detecting antibody-mediated damage to red blood cells (particularly in autoimmune hemolytic anemia), and understanding the difference between them is essential. The direct Coombs test answers the question: "Are there antibodies already bound to the patient's red blood cells?" The test takes the patient's RBCs and adds an anti-human immunoglobulin reagent. If antibodies (or complement) are stuck to the RBC surface, they'll be detected. A positive direct Coombs test indicates that antibodies are actively attacking the patient's own cells. The indirect Coombs test answers a different question: "Are there circulating antibodies in the patient's serum that can bind to RBCs?" This test mixes the patient's serum with donor RBCs. If the patient has free-floating antibodies that can attack RBCs, they'll bind to the donor cells and be detected. This is useful for detecting antibodies before they've bound to the patient's own cells, or in transfusion compatibility testing. Tissue biopsy with immunofluorescence can directly visualize antibody or complement deposition on affected tissues. Typically, linear deposition of immunoglobulin G or complement along basement membranes is seen in Type II hypersensitivity reactions. For example, in Goodpasture syndrome (anti-glomerular basement membrane disease), linear deposits of IgG are visible along the kidney's glomerular basement membrane. Type III Immune Complex-Mediated Hypersensitivity How Immune Complexes Form and Cause Damage Type III hypersensitivity starts with soluble antigen—antigen that's circulating freely in the bloodstream, not fixed to cells. When antibodies encounter these antigens, they form immune complexes: multivalent lattices where multiple antibody molecules cross-link multiple antigen molecules together. Why does the antigen-antibody ratio matter? This is a critical concept that confuses many students. The pathogenicity of immune complexes depends critically on their size: Excess antibody (high antibody-to-antigen ratio) produces large complexes. These large aggregates are efficiently recognized and cleared by macrophages in the liver and spleen, so they cause minimal tissue damage. Optimal (intermediate) ratio produces small to medium-sized complexes. These are the most pathogenic because they're too small to be efficiently cleared by the reticuloendothelial system, but large enough to deposit in vessel walls, the glomeruli of the kidneys, and tissue basement membranes. Excess antigen (high antigen-to-antibody ratio) also produces large complexes that are cleared efficiently. The "sweet spot" for tissue damage is the intermediate ratio that produces small immune complexes—these evade clearance mechanisms and lodge where they cause the most harm. Once complexes deposit in tissues, they activate the classical complement pathway, generating potent fragments like C3a and C5a (called anaphylatoxins because of their inflammatory effects). These fragments recruit neutrophils to the site of deposition. The neutrophils then release damaging enzymes, generate reactive oxygen species (ROS), and cast neutrophil extracellular traps (NETs), all of which cause vasculitis and tissue injury. This is why Type III hypersensitivity characteristically causes inflammation of blood vessel walls. Diagnosis of Type III Hypersensitivity Since Type III hypersensitivity involves complement activation, measuring complement levels in serum helps both diagnose the condition and determine which complement pathway is being activated. Classical pathway activation (the most common pathway in Type III hypersensitivity) consumes the early complement components. Therefore, you'll see reduced C4 and C3 levels. The classic disease demonstrating this pattern is systemic lupus erythematosus (SLE), where circulating immune complexes containing lupus antigens activate the classical pathway and deplete C3 and C4. Alternative pathway activation produces a different complement consumption pattern: reduced complement factor B, properdin, and C3 levels (but typically normal C4, since C4 is part of the classical pathway). This pattern is seen in membranoproliferative glomerulonephritis (especially the post-infectious form and the form associated with C3 nephritic factor). The key principle: complement levels drop as they're consumed during activation, so low complement = active immune complex disease. You may also see tissue biopsy with immunofluorescence showing granular (rather than linear) deposits of immunoglobulin and complement in the glomeruli or other affected tissues—this granular pattern reflects the scattered deposition of multiple small immune complexes, whereas Type II reactions show a linear pattern from antibodies uniformly coating a basement membrane. Management of Type III Hypersensitivity Treatment of Type III hypersensitivity is tailored to the underlying disease causing the circulating antigens. Approaches typically include: Corticosteroids to suppress the inflammatory response driven by neutrophils and complement activation Immunosuppressive agents to reduce antibody production (such as mycophenolate or azathioprine) Complement-inhibiting strategies, an emerging class of therapies that can block complement activation at various points in the cascade <extrainfo> The specific management depends on whether the antigen is infectious (like streptococcal antigens in post-streptococcal glomerulonephritis, which may resolve with antibiotic treatment), autoimmune (like in SLE, requiring long-term immunosuppression), or from another source. </extrainfo>